Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
7
×
boston blog main
boston top stories
life sciences
national blog main
7
×
clinical trials
fda
national top stories
new york blog main
new york top stories
rna interference
boston
patisiran
regeneron pharmaceuticals
san diego blog main
san diego top stories
akcea therapeutics
drugs
hereditary transthyretin amyloidosis
inotersen
onpattro
san francisco blog main
san francisco top stories
tafamidis
amgen
biotech
deals
inclisiran
new york
pcsk9 inhibitors
pfizer
vyndaqel
acute hepatic porphyrias
akin akinc
alirocumab
ambys medicines
amicus therapeutics
aminolevulinic acid
ampio pharmaceuticals
andrew fire
What
fda
7
×
drug
alnylam
medicine
rna
rnai
ago
cholesterol
gene
interference
medco
medicines
patients
pharmaceuticals
uses
acquire
afternoon
agreed
alnylam’s
approval
approve
approved
approves
aren’t
awaits
billion
bio
biological
bringing
brings
cash
cells
clears
closer
company
compound
crossed
deal
decades
decision
Language
unset
Current search:
" national blog main "
×
fda
×
" alnylam pharmaceuticals "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision